EyePoint Pharmaceuticals

Press Releases

pSivida Enhances Board of Directors with Election of Veteran Healthcare Executive Kristine Peterson
Jun 28, 2017
WATERTOWN, Mass. , June 28, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced that Kristine Peterson , a seasoned healthcare executive has been elected to the Company's Board of
pSivida Submits Marketing Authorization Application (MAA) for Approval of Durasert™ Three-year Treatment for Posterior Segment Uveitis in the European Union
Jun 22, 2017
WATERTOWN, Mass. , June 22, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA), seeking approval to market
pSivida's Durasert™ Three-year Treatment for Posterior Segment Uveitis Successfully Achieves Primary Efficacy Endpoint in Second Phase 3 Study
Jun 13, 2017
Highly Significant Difference Observed Between Durasert and Control Group  in Primary Efficacy Analysis of Prevention of Uveitis Recurrence Conference Call Today at 4:30 p.m.ET WATERTOWN, Mass. , June 13, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of
Durasert™ Three-year Treatment for Posterior Segment Uveitis Significantly Reduces Recurrences Through 12 Months
May 08, 2017
Positive Data Presented at the Association for Research in Vision and Ophthalmology Annual Meeting pSivida Anticipates Reporting Top Line Results from the Second Pivotal Phase 3 Clinical Trial in June 2017 WATERTOWN, Mass. , May 08, 2017 (GLOBE NEWSWIRE) -- pSivida Corp.
pSivida Corp. Reports Fiscal 2017 Third Quarter Results; Key Milestones on Track
May 04, 2017
 EU and US Calendar 2017 Registration Filing Milestones for Durasert™ for Posterior Segment Uveitis Remain on Schedule Conference Call and Webcast Today, May 4th , at 4:30 p.m. ET WATERTOWN, Mass. , May 04, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development
pSivida Corp. to Report Third Quarter Fiscal Year 2017 Financial Results on Thursday, May 4th
Apr 19, 2017
WATERTOWN, Mass. , April 19, 2017 (GLOBE NEWSWIRE) -- pSivida Corp.  (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for treating eye diseases, today announced its financial results for the third quarter of fiscal year 2017 will be released
Abstract on pSivida's Treatment of Posterior Segment Uveitis Accepted for Presentation at the 2017 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Mar 15, 2017
WATERTOWN, Mass. , March 15, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced that an abstract supporting the Company's Durasert three-year treatment for posterior segment uveitis has
pSivida to Present at the 2017 BIO CEO & Investor Conference
Feb 10, 2017
WATERTOWN, Mass. , Feb. 10, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products, announced today that Nancy Lurker , President and Chief Executive Officer, is scheduled to present an overview of the company and its progress
pSivida Corp. Reports Fiscal 2017 Second Quarter and First Half Results
Feb 07, 2017
EU and U.S. 2017 Registration Filing Milestones for Durasert™ for Posterior Segment Uveitis Remain on Track Conference Call and Webcast Today, February 7 , at 4:30 p.m. ET WATERTOWN, Mass. , Feb. 07, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of
pSivida Corp. Announces Second Quarter Fiscal Year 2017 Financial Results Release Date and Conference Call Information
Jan 25, 2017
WATERTOWN, Mass. , Jan. 25, 2017 (GLOBE NEWSWIRE) -- pSivida Corp.  (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for treating eye diseases, today announced its financial results for the second quarter of fiscal year 2017 will be released
Seasoned Ophthalmology Executive Deb Jorn Joins pSivida to Focus on Corporate and Commercial Development
Nov 07, 2016
WATERTOWN, Mass. , Nov. 07, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, announced that Deb Jorn , a proven business development executive, has joined the Company as Executive Vice President of
pSivida Corp. Reports Fiscal 2017 First Quarter Results and Provides Update on Corporate Objectives & Milestone Timeline
Nov 07, 2016
New Leadership Focused on Increasing Commercial Potential of Proven Durasert ™ Sustained Release Platform Company Continues Focus on MAA and NDA Filings for Uveitis Product in 2017 Conference Call and Webcast Today, November 7 , at 4:30 p.m. ET WATERTOWN, Mass. , Nov.
pSivida Corp. Announces First Quarter Fiscal Year 2017 Financial Results Release Date and Conference Call Information
Oct 31, 2016
WATERTOWN, Mass. , Oct. 31, 2016 (GLOBE NEWSWIRE) -- pSivida Corp.  (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for treating eye diseases, today announced its financial results for the first quarter of fiscal year 2017 will be released
Phase 3 trial of Medidur™ in Posterior Segment Uveitis Meets Enrollment Target
Oct 04, 2016
Study is the Second of Two Ongoing Phase 3 Trials in Support  Of Product Registration in the US EU Filing Remains on Track for 1Q2017 Filing WATERTOWN, Mass. , Oct. 04, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug technologies
pSivida Corp. Strengthens Board of Directors With Leading Ophthalmologist
Sep 27, 2016
WATERTOWN, Mass. , Sept. 27, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA),  a leader in the development of sustained release drug delivery products for treating eye diseases, today announced the appointment of Jay S. Duker , M.D, to the Company's Board of Directors.  Dr.
pSivida to Present at the Ladenburg Thalmann Annual Healthcare Conference
Sep 22, 2016
WATERTOWN, Mass. , Sept. 22, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced today that Nancy Lurker , the Company's newly-appointed President and Chief Executive Officer,
pSivida Reports Inducement Awards to New President and Chief Executive Officer
Sep 20, 2016
WATERTOWN, Mass. , Sept. 20, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, today reported the grant of inducement awards to its new President and Chief Executive Officer, Nancy
pSivida Implements Leadership Change -- Nancy Lurker Named as President and CEO
Sep 15, 2016
WATERTOWN, Mass. , Sept. 15, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced that its Board of Directors has appointed Nancy Lurker as its President and Chief Executive
pSivida Corp. Provides Company Update and Reports Fourth Quarter and FY 2016 Results
Sep 12, 2016
WATERTOWN, Mass. , Sept. 12, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today provided a Company update and announced financial results for its fourth quarter and fiscal year
pSivida Corp. Announces Fourth Quarter and Fiscal Year 2016 Financial Results Release Date and Conference Call Information
Sep 01, 2016
WATERTOWN, Mass. , Sept. 01, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for treating eye diseases, today announced its financial results for the fourth quarter and fiscal year 2016 will be
Displaying 41 - 60 of 316
EyePoint Pharmaceuticals